Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1777P - Launching local treatment guidelines for stage IV cancer during COVID-19 pandemic using ESMO MCBS

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Rasha Aboelhassan

Citation

Annals of Oncology (2020) 31 (suppl_4): S934-S973. 10.1016/annonc/annonc289

Authors

R.A.M. Aboelhassan1, M.H. Ali2, A. Mohamed3, A. Mosa3

Author affiliations

  • 1 Clinical Oncology Department, Nasser Institute for Research and Treatment, 1351 - Cairo/EG
  • 2 Clinical Pharmacology Department, Nasser Institute for Research and Treatment, 1351 - Cairo/EG
  • 3 Radiation Therapy Department, Nasser Institute for Research and Treatment, 1351 - Cairo/EG
More

Resources

Abstract 1777P

Background

Treatment of stage IV cancer during COVID19 pandemic is a challenge, and we need to maintain survival benefit, patient safety, and health care resources at the same time.

Methods

We used the ESMO-MCBS (Forms version 1.1 and cards) and ESMO recommendations for COVID-19 pandemic to launch local guidelines for first-line therapy for ABC, NSCLC and mCRC comparing ESMO-MCBS for the standard therapy (ST) and COVID-19 pandemic therapy (COT). We then compared prices (EGP) and price changes (PC).

Results

General rules: For PS≥3 patients, chemotherapy was postponed. We applied COVID-19 precautions to all patients. Oral chemotherapy was the preferred option: Every three weeks regimens were preferred over weekly regimens. ABC: Anti CDK4/6 are still the best option for patients with HR+ HER2- in non-visceral crisis, with MCBS 3 or 4. TNBC: carboplatin-containing therapy is still the best option. HER2+3 Addition of carboplatin to combination of trastuzumab and paclitaxel every three weeks was confirmed to increase treatment benefit, PFS of 13.8 v 7.6 months (P=.005) (HR, 0.55; 95% CI, 0.46 to 0.64), RR (42% v 29%) MCBS for carboplatin=3, which is the COT (JCO 2006, 24:2786). Weekly trastuzumab + paclitaxel + carboplatin confirmed improvement in RR compared with every 3 weeks (42% versus 29%) l with an unadjusted odds ratio of 1.75 (P.0004). With limited survival benefit, and toxicity profile (JCO 2008:26:1642) MCBS for weekly regimen=1 using form 2C which is the current ST. mCRC all RAS wild type No change for the use of FOLFRI + cetuximab: MCBS=4 using an infusion pump for 5FU with certain precautions. NSCLC: No change as regard to recommendation for targeted therapy whenever there were indications for a patient with gene mutation: MCBS=4. Immunotherapy for patients with PDL1≥50%, only MCBS=5. Pemetrexed with cisplatin is the recommended option for a patient with PS ≥1 and PDL1<50 with MCBS=4. RTH: Palliative quick course RTH Table: 1777P

ESMO-MCBS and price changes for ABC, NSCLC and mCRC before and after COVID-19 pandemic in selected protocols.

Scenario ST ST MCBS ST price ST MCBS reference COT COT price COT MSBS COT MCBS reference change of MCBS change of price
Form Form
ABC with HER2- HR+ visceral crisis docetaxel every three weeks 4 3000 Cancer 2008; 112:1455 oral vinorelbine 12000 3 Breast:2019 Jun; 45:7-14 -1 +3
2C 2C
mCRC RAS gene mutation IFL/ bevacizumab 3 15000 N Engl J Med 2004; 350:2335 capecitabine/bevacizumab 15000 3 Lancet Oncol. 2013; 14:1077–85. 0 0
2A 2B
NSCLC PS=2 single agent paclitaxel or gemcitabine or vinorelbine 3 5000 J Thorac Oncol. 2008; 3: 728 oral vinorelbine 10000 3 ANTICANCER RESEARCH 32: 175-182 (2012) 0 +1
2C 2C
.

Conclusions

Maintaining use of ESMO-MCBS during the COVID-19 pandemic is possible with some changes in use of healthcare resources.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings